{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:48:39Z","timestamp":1771012119104,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.mehy.2007.02.025","type":"journal-article","created":{"date-parts":[[2007,4,11]],"date-time":"2007-04-11T11:13:24Z","timestamp":1176290004000},"page":"964-965","source":"Crossref","is-referenced-by-count":3,"title":["Huntington\u2019s disease and HDACi: Would sulpiride and valproate be of therapeutic value?"],"prefix":"10.1016","volume":"69","author":[{"given":"L.","family":"Tremolizzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Rodriguez-Menendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"DiFrancesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Galbussera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Appollonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ferrarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2007.02.025_bib1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1073\/pnas.0510341103","article-title":"The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases","volume":"103","author":"Simonini","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2007.02.025_bib2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrn1989","article-title":"Histone deacetylase inhibitors as therapeutics for polyglutamine disorders","volume":"7","author":"Butler","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.mehy.2007.02.025_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2007.02.025_bib4","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockey","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2007.02.025_bib5","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington\u2019s disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2007.02.025_bib6","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2007.02.025_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987707001831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987707001831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T09:50:50Z","timestamp":1546941050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987707001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0306987707001831"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2007.02.025","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}